Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

2.0K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.0K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.1K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.5K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.5K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.5K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

852
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
852
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

1.4K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis, care pathways, and Complementary and Alternative Medicine (CAM) use among digestive cancer patients in Benin: a qualitative study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Diabetes, impaired fasting glucose, and cognitive trajectories: a multi-cohort study.

medRxiv : the preprint server for health sciences·2026
Same author

Performance of six screening scores for obstructive sleep apnoea in an African population: findings from the BeSAS cross-sectional study.

Sleep medicine: X·2026
Same author

Attitudes Toward Deprescribing Among Community-Dwelling Adults: A Cross-Sectional Study in Community Pharmacies.

Drugs & aging·2026
Same author

Influence of hepatic steatosis on antiseizure drug metabolism: in vitro evidence from differentiated HepaRG cells.

Toxicology letters·2026
Same author

EEG coverage in Africa: How can the gap be covered?

Epilepsy research·2026

Related Experiment Video

Updated: Feb 24, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.6K

Antiepileptic Treatments in Developing Countries.

Jeremy Jost1, Athanase Millogo1,2, Pierre-Marie Preux1

  • 1INSERM, Univ. Limoges, CHU Limoges, UMR_S 1094, Tropical Neuroepidemiology, Institute of Neuroepidemiology and Tropical Neurology, CNRS FR 3503 GEIST, F-87000 Limoges, France.

Current Pharmaceutical Design
|August 12, 2017
PubMed
Summary
This summary is machine-generated.

Millions in developing nations face epilepsy stigma and inadequate treatment due to myths and poor access to antiepileptic drugs. Education campaigns are crucial for improving epilepsy management and patient outcomes globally.

Keywords:
Epilepsyantiepileptics drugsdeveloping countriespatients.stigmatreatment gap

More Related Videos

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.7K
Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture
09:06

Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture

Published on: December 22, 2016

10.1K

Related Experiment Videos

Last Updated: Feb 24, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.6K
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.7K
Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture
09:06

Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture

Published on: December 22, 2016

10.1K

Area of Science:

  • Neurology
  • Global Health
  • Public Health

Background:

  • Epilepsy impacts 70 million worldwide, predominantly in developing countries.
  • Myths, stigma, and discrimination create significant barriers for epilepsy patients.
  • Inadequate, false, or dangerous knowledge, attitudes, and practices regarding epilepsy are prevalent.

Purpose of the Study:

  • To outline the current situation of epilepsy care in developing countries.
  • To analyze the factors influencing the use of antiepileptic drugs in these regions.

Main Methods:

  • Review of the global epilepsy treatment landscape.
  • Analysis of determinants affecting antiepileptic drug utilization.

Main Results:

  • A treatment gap exceeding 75% exists in low-income countries, exacerbated in rural areas.
  • Key barriers include accessibility, availability, affordability, lack of trained personnel, and cultural beliefs.
  • Consultation with traditional healers often precedes modern medical care, delaying treatment.

Conclusions:

  • Information and education campaigns are essential for the general population and healthcare workers.
  • Progress in epilepsy management in developing countries necessitates widespread educational initiatives.
  • Addressing stigma and improving access to antiepileptic drugs are critical for better patient outcomes.